Currently, there are 5.90M common shares owned by the public and among those 5.75M shares have been available to trade.
The company’s stock has a 5-day price change of 373.20% and 6.72% over the past three months. PSTV shares are trading 24.35% year to date (YTD), with the 12-month market performance down to -17.34% lower. It has a 12-month low price of $0.24 and touched a high of $2.67 over the same period. PSTV has an average intraday trading volume of 8.12 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 36.37%, 25.17%, and -0.95% respectively.
Institutional ownership of Plus Therapeutics Inc (NASDAQ: PSTV) shares accounts for 11.50% of the company’s 5.90M shares outstanding.
It has a market capitalization of $8.43M and a beta (3y monthly) value of 0.45. The earnings-per-share (ttm) stands at -$2.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 82.69% over the week and 37.29% over the month.
Earnings per share for the fiscal year are expected to increase by 54.36%, and 23.00% over the next financial year. EPS should shrink at an annualized rate of 29.07% over the next five years, compared to 68.20% over the past 5-year period.
Looking at the support for the PSTV, a number of firms have released research notes about the stock. Ladenburg Thalmann stated their Buy rating for the stock in a research note on January 25, 2021, with the firm’s price target at $8. Maxim Group coverage for the Plus Therapeutics Inc (PSTV) stock in a research note released on October 16, 2020 offered a Buy rating with a price target of $6.
